参考文献

［1］Misra A,Garg A.Clinical features and metabolic derangements in acquired generalized lipodystrophy:case reports and review of the literature[J].Medicine,2003,82(2):129.

［2］项坤三.特殊类型糖尿病［M］.上海：上海科学技术出版社，2011：289—314.

［3］Pope E,Janson A,Khambalia A,et al.Childhood acquired lipodystrophy:aretrospectivestudy[J].Journal of the American Academy of Dermatology,2006,55(6):947—950.

［4］Misra A,Garg A.Clinical features and metabolic derangements in acquired generalized lipodystrophy:case reports and review of the literature[J].Medicine,2003,82(2):129.

［5］Bingham A,Mamyrova G,Rother K I,et al.Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity[J].Medicine(Baltimore),2008,87:70—86.

［6］Billings J K,Milgraum S S,Gupta A K,et al.Lipoatrophic panniculitis:a possible autoimmune inflammatory disease of fat:report of three cases[J].Archives of Dermatology,1987,123(12):1662—1666.(https://www.daowen.com)

［7］申金付，李娟，郭景章.脂肪萎缩性糖尿病一例报道及文献复习［J］.实用糖尿病杂志，2010，6（2）：22—23.

［8］Meehan C A,Cochran E,Kassai A,et al.Metreleptin for injection to treat the complications of leptin deficiency inpatients with congenital or acquired generalized lipodystrophy[J].Expert Review of Clinical Pharmacology,2016,9(1):59—68.

［9］Araujo-Vilar D,Sanchez-Iglesias S,Guillin-amarelle C,et al.Recombinant human leptin treatment in genetic lipodystrophy:the long-term Spanish experience[J].Endocrine,2015,49(1):139—147.

［10］Lupsa B C,Sachdev V,Lungu A O,et al.Cardiomyopathy in congenital and acquired generalized lipodystrophy:a clinical assessment[J].Medicine(Baltimore),2010,89:245—250.

［11］Misra A,Garg A.Clinical features and metabolic derangements in acquired generalized lipodystrophy:case reports and review of the literature[J].Medicine(Baltimore),2003,82:129—146.

［12］Brown R J,Araujo-Vilar D,Cheung P T,et al.The diagnosis and management of lipodystrophy syndromes:a multi-society practice guideline[J].The Journal of Clinical Endocrinology and Metabolism,2016,101:4500—4511.